This project belongs to the field of integrated traditional Chinese and Western medicine oncology. Gastric cancer is one of the most common malignant tumors, ranking fifth in incidence among malignant tumors worldwide and third in mortality rate. Comprehensive treatment mainly with surgery, radiotherapy, and chemotherapy has not seen new breakthroughs in the efficacy for advanced gastric cancer. The research team adheres to Professor Qiu Jiaxin's (a famous traditional Chinese medicine practitioner in Shanghai) academic thought that 'deficiency of spleen qi is a fundamental factor in the occurrence and development of gastric cancer,' combining disease differentiation and syndrome differentiation. They conduct series of clinical and mechanism studies targeting different stages of gastric cancer (post-surgery, late stage) as well as different populations, systematically evaluating the effectiveness and safety of traditional Chinese medicine treatment for gastric cancer. A precise diagnosis and treatment plan for gastric cancer based on 'spleen strengthening method' has been formed and promoted, extending the overall survival time of patients with advanced gastric cancer. Improved prognosis. Three innovative achievements were formed: (1) Established a new model for the diagnosis and treatment of gastric cancer based on spleen strengthening and combining disease patterns: Based on the pathogenesis theory of spleen deficiency in gastric cancer, combined with abnormal gene regulatory mechanisms related to gastric cancer, an innovative model for the diagnosis and treatment of gastric cancer focusing on spleen strengthening and combining disease patterns was proposed. This model has been applied to different stages of advanced gastric cancer as well as different populations, forming standardized diagnostic and treatment plans for gastric cancer and becoming the 'Traditional Chinese Medicine Diagnosis and Treatment Plan for Gastric Cancer' and the 'Clinical Pathway for Gastric Cancer Disease Type' issued by the National Administration of Traditional Chinese Medicine. (2) Proven that spleen strengthening therapy can extend the survival period of various types of gastric cancer: It was the first to carry out an international registered, large-sample, multicenter clinical study in the field of traditional Chinese medicine for gastric cancer. The overall survival (OS) and disease-free survival (DFS) were compared among 3806 cases of advanced gastric cancer. It has been confirmed that the traditional Chinese medicine treatment based on spleen strengthening method significantly prolongs survival and improves symptoms of spleen deficiency in both stage II-III gastric cancer after radical surgery and different populations with advanced gastric cancer. The median survival time (OS) for Chinese medicine combined with chemotherapy in newly diagnosed cases of advanced gastric cancer reached 19.3 months; the one-, two-, and three-year disease-free survival rates after radical surgery followed by Chinese medicine combined with chemotherapy were 87%, 84%, and 80% respectively for stage II-III gastric cancer; for high-risk recurrence and metastasis cases after radical surgery, the one-, two-, and three-year disease-free survival rates were 84%, 59%, and 49% respectively for stage IIIc gastric cancer, with better efficacy than that of standard treatment at the same period. It has also revealed the therapeutic mechanism of spleen strengthening compound in regulating PTBP3-related effects: starting from the combination of efficacy and traditional Chinese medicine pathogenesis theory, it was first confirmed that there is a disorder in the selective splicing function related to post-transcriptional regulatory factor PTBP3 in gastric cancer. It was found that PTBP3 can regulate the expression of different splicing isoforms of genes such as Stat3 and Bcl-2, promoting gastric cancer cell proliferation and inhibiting apoptosis. Combining with the classical prescription effect, it proposes an innovative viewpoint that 'the disorder of selective splicing related to PTBP3 is a part of the pathological basis for spleen deficiency syndrome in gastric cancer.' It confirms that the inhibitory effect of spleen-strengthening compound prescriptions on gastric cancer cell growth is related to PTBP3's regulation of Stat3 splicing isoforms through selective splicing, revealing the internal relationship of gene expression changes after intervention with spleen-strengthening compound prescriptions, laying the foundation for precise treatment of gastric cancer with traditional Chinese medicine. This achievement has established a standardized clinical pathway for the treatment of gastric cancer with spleen-strengthening methods and a precise diagnosis and treatment plan centered on spleen-strengthening for gastric cancer syndrome, improving the clinical efficacy of traditional Chinese medicine in treating gastric cancer. It has revealed the efficacy mechanism, inherited and developed the academic thought of 'spleen deficiency in gastric cancer'. It has successively obtained funding from 6 projects including National Natural Science Foundation of China and Ministry of Science and Technology of China. It has published 28 papers, with a total of 233 positive citations, among which 6 papers were included in SCI (2 with an impact factor exceeding 5). It has trained 21 graduate students. It has participated in 11 domestic and international academic conferences, including 6 keynote presentations. It has promoted Longhua Hospital to become the leader unit of the national traditional Chinese medicine administration's cooperative group for gastric cancer disease classification. The precise diagnosis and treatment plan centered on spleen-invigorating method for gastric cancer combined with syndrome differentiation has been applied in hospitals nationwide as well as in Singapore, Thailand, and other foreign countries, achieving good social and economic benefits.